Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Haiyan Zhang. (2021) Bridging antifungal prophylaxis with micafungin in hematopoietic stem cell transplantation: a retrospective analysis. Hematology 26:1, pages 670-674.
Read now
Read now
Pola de la Torre & Annette C Reboli. (2014) Micafungin: An Evidence-Based Review of its Place in Therapy. Core Evidence 9, pages 27-39.
Read now
Read now
Articles from other publishers (24)
Asmaa Ferdjallah, Jo-Anne H. Young & Margaret L. MacMillan. (2021) A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. Frontiers in Pediatrics 9.
Crossref
Crossref
Ling Ye, Jiaxing Zhang, Wei Xiao & Shuwen Liu. (2020) Efficacy and mechanism of actions of natural antimicrobial drugs. Pharmacology & Therapeutics 216, pages 107671.
Crossref
Crossref
Achim Rothe, Annika Claßen, Jonathan Carney, Michael Hallek, Sibylle C. Mellinghoff, Christoph Scheid, Udo Holtick & Michael Bergwelt‐Baildon. (2020) Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis. European Journal of Haematology 104:4, pages 291-298.
Crossref
Crossref
Antonio Vena, Emilio Bouza, Matteo Bassetti, Francesco Menichetti, Maria Merelli, Santiago Grau, Jesús Fortun, María Isabel Sánchez, José María Aguado, Paloma Merino, Francisco Bonache & Patricia Muñoz. (2020) Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study. Infectious Diseases and Therapy 9:1, pages 151-163.
Crossref
Crossref
Maria Kotsopoulou, Christina Papadaki, Konstantinos Anargyrou, Alexandros Spyridonidis, Ioannis Baltadakis, Helen A. Papadaki, Maria Angelopoulou, Vasiliki Pappa, Kleoniki Liakou, Manto Tzanetakou, Marina Moustaka & George Vassilopoulos. (2019) Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study. Infectious Diseases and Therapy 8:2, pages 255-268.
Crossref
Crossref
Magdalini Tsekoura, Maria Ioannidou, Zoi-Dorothea Pana, Anna-Bettina Haidich, Charalampos Antachopoulos, Elias Iosifidis, George Kolios & Emmanuel Roilides. (2019) Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children. Pediatric Infectious Disease Journal 38:1, pages 42-49.
Crossref
Crossref
E W Muilwijk, J A Maertens, W J F M van der Velden, R ter Heine, A Colbers, D M Burger, D Andes, K Theunissen, N M A Blijlevens & R J M Brüggemann. (2018) Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. Journal of Antimicrobial Chemotherapy 73:11, pages 3095-3101.
Crossref
Crossref
Laura L. Kovanda, Thomas J. Walsh, Daniel K. Benjamin, Antonio Arrieta, David A. Kaufman, P. Brian Smith, Paolo Manzoni, Amit V. Desai, Atsunori Kaibara, Peter L. Bonate & William W. Hope. (2018) Exposure–Response Analysis of Micafungin in Neonatal Candidiasis. Pediatric Infectious Disease Journal 37:6, pages 580-585.
Crossref
Crossref
A. Vena, E. Bouza, A. Álvarez-Uría, J. Gayoso, P. Martín-Rabadán, F. Cajuste, J. Guinea, J. Gómez Castellá, R. Alonso & P. Munoz. (2017) The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin. Clinical Microbiology and Infection 23:12, pages 1000.e1-1000.e4.
Crossref
Crossref
Akash Patil & Soumyajit Majumdar. (2017) Echinocandins in antifungal pharmacotherapy. Journal of Pharmacy and Pharmacology 69:12, pages 1635-1660.
Crossref
Crossref
Lesley J. Scott. (2017) Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients. Pediatric Drugs 19:1, pages 81-90.
Crossref
Crossref
Sonia Luque, Nuria Campillo, Francisco Álvarez-Lerma, Olivia Ferrández, Juan Pablo Horcajada & Santiago Grau. (2016) Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. Enfermedades Infecciosas y Microbiología Clínica 34:10, pages 652-654.
Crossref
Crossref
A. Lepak, K. Marchillo, J. VanHecker, N. Azie & D. Andes. (2016) Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. Antimicrobial Agents and Chemotherapy 60:1, pages 674-677.
Crossref
Crossref
Sudarshan Singh Rathore, Jayapradha Ramakrishnan & Thiagarajan Raman. 2016. Recent Trends in Antifungal Agents and Antifungal Therapy. Recent Trends in Antifungal Agents and Antifungal Therapy
149
173
.
Chie Kobayashi, Tomoko Hanadate, Toshiro Niwa, Takashi Yoshiyasu, Masahiro So & Keita Matsui. (2015) Safety and Effectiveness of Micafungin in Japanese Pediatric Patients. Journal of Pediatric Hematology/Oncology 37:5, pages e285-e291.
Crossref
Crossref
Chie Kobayashi, Tomoko Hanadate, Toshiro Niwa, Yasuno Hirano, Takashi Yoshiyasu, Masahiro So & Keita Matsui. (2015) Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study. Journal of Infection and Chemotherapy 21:6, pages 438-443.
Crossref
Crossref
Emilio Bouza, Jesús Guinea & María Guembe. (2014) The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. Antibiotics 4:1, pages 1-17.
Crossref
Crossref
Claudio Viscoli, Matteo Bassetti, Elio Castagnola, Simone Cesaro, Francesco Menichetti, Sandra Ratto, Carlo Tascini & Daniele Roberto Giacobbe. (2014) Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infectious Diseases 14:1.
Crossref
Crossref
S.M. Heimann, M.J.G.T. Vehreschild, L. Meintker, W. Heinz, T. Schroeder, M. von Bergwelt‐Baildon, O.A. Cornely & J.J. Vehreschild. (2014)
Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato‐oncological high‐risk patients: a web‐based non‐interventional trial in four large university hospitals in
G
ermany
. Transplant Infectious Disease 16:6, pages 968-974.
Crossref
Crossref
Daniel K. Benjamin, Jaime G. Deville, Nkechi Azie, Laura Kovanda, Mike Roy, Chunzhang Wu & Antonio Arrieta. (2013) Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis. Pediatric Infectious Disease Journal 32:11, pages e419-e425.
Crossref
Crossref
Lesley J. Scott. (2012) Micafungin. Drugs 72:16, pages 2141-2165.
Crossref
Crossref
Chin Fen Neoh, David C. M. Kong, Monica A. Slavin & Sharon C.-A. Chen. (2012) Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins. Current Fungal Infection Reports 6:2, pages 95-106.
Crossref
Crossref
Andrew J. Ullmann & Wibke Klaas. (2012) Safety of micafungin in prospective and retrospective clinical trials. Mycoses 55, pages 58-64.
Crossref
Crossref
Oliver A. Cornely, Francisco M. Marty, Flavie Stucker, Peter G. Pappas & Andrew J. Ullmann. (2011) Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses 54:6, pages e838-e847.
Crossref
Crossref